Message us on WhatsApp
    YouMedicine.co - Regenerative Medicine
    ENES
    Peptide libraryVersión en español

    Educational guide · Medellín, Colombia

    Peptide therapy in Medellín: a 20-compound guide to evidence, safety and clinic questions

    Considering peptide therapy in Medellín or El Poblado? This evidence-led guide compares 20 compounds, explains what research can—and cannot—show, and helps you prepare questions for a medical consultation.

    The short answer

    There is no single “best peptide” for everyone. Some peptide-based medicines have strong evidence for specific diagnoses and approved products; many compounds promoted for recovery, anti-aging or performance have only laboratory, animal or early-stage data.

    This is an educational comparison, not a tier list, prescription or claim that YOU Medicine offers every item. The exact product, indication, evidence, risks and local authorization matter more than online rankings.

    What “best” should mean in medicine

    For a patient, “best” means a treatment that fits a confirmed diagnosis, has evidence for that exact use, has a reliable product and safety plan, and is legal and appropriately supervised. Popularity, influencer posts, potency claims and a long list of mechanisms are not substitutes.

    Peptides are not one therapeutic class with one risk profile. A labeled medicine such as semaglutide is not equivalent to an unapproved research vial such as BPC-157, and evidence for one compound does not transfer to another.

    How to read the evidence

    • Higher confidence: replicated controlled trials and a current product label for the exact indication and population.
    • Intermediate: randomized early-phase trials that show a signal but need confirmation, longer follow-up or regulatory review.
    • Low: small, uncontrolled, regional or indirect human studies; mechanisms and biomarkers alone do not establish patient benefit.
    • Preclinical: cell or animal experiments. These can guide research but do not prove effectiveness or safety in people.
    • Unknown: no adequate human evidence or product-specific safety data found. “Not proven” does not mean “proven ineffective”; it means the claim cannot be relied on.

    At-a-glance comparison of 20 peptides

    CompoundResearch areaResearch stageEvidence level
    BPC-157Tissue-repair researchMostly preclinical; very limited human dataVery low for clinical treatment claims
    TB-500Tissue-repair researchPreclinical and analytical literature; human treatment evidence lackingVery low / insufficient
    GHK-CuSkin and hair researchTopical/cosmetic and laboratory researchLow; formulation-specific clinical evidence is limited
    CJC-1295Growth-hormone signalingEarly human pharmacology; no proven wellness outcomeLimited human hormone-marker data
    IpamorelinGrowth-hormone signalingPreclinical pharmacology; limited clinical exposureInsufficient for wellness or recovery claims
    SemaglutideMetabolic medicineProduct-specific, established prescription usesHigh for labeled products and indications
    TirzepatideMetabolic medicineProduct-specific, established prescription usesHigh for labeled products and indications
    RetatrutideInvestigational metabolic medicinePhase 2 evidence in cited publications; current status must be recheckedModerate early-stage trial evidence; not established routine care
    TesamorelinGrowth-hormone signalingEstablished narrow U.S. label; other uses are not established by that labelModerate/high for the specific labeled population
    AOD-9604Metabolic researchHistorical development and limited clinical evidenceInsufficient for weight-loss claims
    MOTS-cMitochondrial and metabolic researchCell and animal research; early human biomarker studiesPreclinical/early; no established therapy
    EpitalonAging-biology researchCell/animal studies and low-certainty human literatureVery low for longevity claims
    Thymosin alpha-1Immune-related researchCondition-specific clinical research; regulatory status variesMixed and indication-specific
    KPVInflammation researchPreclinical and delivery researchVery low for human treatment claims
    SelankNeurobehavioral researchLimited human mechanistic and animal studiesLow/insufficient for routine anxiety treatment
    SemaxNeurological researchLimited regional and experimental literatureLow/insufficient for general cognitive enhancement
    DSIPSleep researchSmall historical human study; unresolved basic biologyVery low for insomnia treatment
    KisspeptinReproductive endocrinologyHuman physiology and condition-specific reproductive researchStrong for pathway biology; clinical uses remain specific
    Bremelanotide (PT-141)Sexual-health medicineNarrow U.S. prescription indicationModerate/high for the labeled population and outcomes
    CagrilintideInvestigational metabolic medicinePhase 2 monotherapy and later combination researchModerate early-stage evidence; approval status must be checked

    The 20 peptide profiles: uses, evidence, risks and status

    BPC-157

    Tissue-repair research

    Very low for clinical treatment claims
    What it is
    BPC-157 is a synthetic 15-amino-acid peptide studied in laboratory and animal models. It is often marketed online for recovery, but marketing language is not proof of a human treatment benefit.
    How it works
    Reviews discuss proposed effects on tissue-repair signaling, nitric-oxide pathways and angiogenesis. These mechanisms are largely preclinical and have not been established as clinically useful in people.
    What it is being studied for
    Research has examined musculoskeletal injury, gastrointestinal injury and other models, mainly in animals. One retrospective report describes knee-pain patients, but it is not a randomized controlled trial.
    Potential benefits
    A possible effect on tissue healing is a research hypothesis, not a proven benefit. The available human evidence is insufficient to recommend it for an injury or other condition.
    Evidence and limitations
    A 2025 systematic review found a literature dominated by preclinical work and very sparse clinical evidence. The small observational report cannot establish cause, effectiveness or safety.
    Known risks and limitations
    The FDA warns that compounded BPC-157 may pose immunogenicity and peptide-impurity risks; human safety information is inadequate. Product identity, sterility and dose consistency are additional concerns with unverified sources.
    Regulatory status
    No FDA-approved BPC-157 medicine is identified in the cited sources. Colombian/INVIMA registration for any specific formulation was not verified; do not assume approval or clinic availability.

    Selected research references

    TB-500

    Tissue-repair research

    Very low / insufficient
    What it is
    TB-500 is a name used for a short fragment associated with thymosin beta-4. It should not be treated as interchangeable with a full-length thymosin beta-4 medicine or with a standardized, approved product.
    How it works
    Thymosin beta-4 biology is studied in cell movement and tissue repair. Findings about a full-length molecule or laboratory fragment do not establish the effects of products sold as TB-500 in humans.
    What it is being studied for
    The literature located for this review includes peptide-detection and sports-medicine discussions, not reliable clinical trials showing TB-500 treats sports injuries or accelerates recovery.
    Potential benefits
    Tissue-repair benefits are proposed from related laboratory biology. A clinical benefit for TB-500 itself has not been established.
    Evidence and limitations
    There is no robust human efficacy evidence in the sources reviewed. Detection studies show that laboratories can analyze the fragment; they do not show that it is effective or safe as a treatment.
    Known risks and limitations
    The FDA notes potential immunogenicity, aggregation and peptide-impurity concerns for compounded thymosin beta-4 fragment (TB-500). Unverified products add sterility, contamination and mislabeling risks.
    Regulatory status
    The cited FDA material concerns compounding safety, not approval. No product-specific Colombian/INVIMA status was verified, and no clinic availability is claimed.

    Selected research references

    GHK-Cu

    Skin and hair research

    Low; formulation-specific clinical evidence is limited
    What it is
    GHK is a naturally occurring tripeptide that can bind copper to form GHK-Cu. Topical cosmetic products and injectable preparations are different routes and cannot be assumed to have the same evidence or safety.
    How it works
    Laboratory studies propose effects on extracellular-matrix proteins, fibroblasts and repair signaling. Skin penetration, concentration and formulation affect whether a topical product reaches the intended tissue.
    What it is being studied for
    Research and reviews discuss topical skin appearance, wound biology and cosmetic delivery. Evidence for hair growth, injectable use or treatment of disease is not established by these cosmetic and laboratory studies.
    Potential benefits
    A possible skin-quality effect is formulation-dependent and remains uncertain. It should not be presented as a proven anti-aging, wound-healing or hair-restoration treatment.
    Evidence and limitations
    The cited literature includes narrative reviews and work on skin permeation. It does not establish a consistent effect in large, independent clinical trials across products.
    Known risks and limitations
    Topical irritation or sensitivity can occur with cosmetic ingredients; risks of unapproved injectable GHK-Cu are not adequately characterized. Product purity, copper content and sterility require verification.
    Regulatory status
    A cosmetic ingredient listing is not approval of an injectable drug or a disease-treatment claim. Colombia/INVIMA status for any specific product was not verified.

    Selected research references

    CJC-1295

    Growth-hormone signaling

    Limited human hormone-marker data
    What it is
    CJC-1295 is a synthetic, long-acting analog of growth hormone-releasing hormone (GHRH). Products sold with similar names may differ in structure and are not necessarily standardized.
    How it works
    A small controlled study in healthy adults found that CJC-1295 increased growth hormone and IGF-1 markers for a period after administration. A biomarker change does not prove improved strength, appearance, recovery or longevity.
    What it is being studied for
    Human research has focused on pharmacokinetics, hormone levels and short-term safety—not validated anti-aging or sports-performance outcomes.
    Potential benefits
    Theoretical growth-hormone effects are not equivalent to a demonstrated clinical benefit. No general wellness, fat-loss or muscle-building benefit is established by the cited trial.
    Evidence and limitations
    Evidence is limited to early pharmacology. There is no adequate body of large outcome trials supporting routine use for longevity, body composition or injury recovery.
    Known risks and limitations
    The FDA reports serious adverse events associated with CJC-1295, including increased heart rate and systemic vasodilatory reactions, and notes limited clinical data. Hormone-axis effects and product impurities are additional concerns.
    Regulatory status
    No FDA-approved CJC-1295 product is identified in the cited material. Exact Colombian/INVIMA status must be checked for a specific product; no availability is claimed.

    Selected research references

    Ipamorelin

    Growth-hormone signaling

    Insufficient for wellness or recovery claims
    What it is
    Ipamorelin is a synthetic pentapeptide studied as a growth-hormone secretagogue. It is not the same thing as growth hormone, and a proposed secretagogue effect does not establish a medical use.
    How it works
    Early pharmacology work describes stimulation of growth-hormone release through a ghrelin-receptor pathway in experimental systems. Translation from receptor or animal findings to meaningful human outcomes is unproven.
    What it is being studied for
    Research includes experimental pharmacology and intravenous use studied for gastric motility. That investigation does not support use for muscle gain, anti-aging or general recovery.
    Potential benefits
    No dependable benefit for wellness or body composition is established. The FDA has specifically cautioned that available information is insufficient for some administration routes.
    Evidence and limitations
    The foundational paper is preclinical pharmacology. Limited clinical exposure and a concerning FDA safety discussion do not amount to evidence of a safe, effective routine treatment.
    Known risks and limitations
    The FDA cites immunogenicity and peptide-impurity concerns and reports serious adverse events, including deaths, in an intravenous study for gastric motility. It says route-specific safety information is insufficient.
    Regulatory status
    No FDA-approved ipamorelin treatment for wellness is identified. Colombian/INVIMA status is unverified for specific preparations; do not infer approval from online sale or compounding.

    Selected research references

    Semaglutide

    Metabolic medicine

    High for labeled products and indications
    What it is
    Semaglutide is a GLP-1 receptor agonist available in several prescription products. The indication, dose form and labeling differ by brand; one product's authorization must not be generalized to all preparations.
    How it works
    It acts at GLP-1 receptors involved in glucose regulation and appetite signaling. Its effects include glucose-dependent insulin secretion and slower gastric emptying; individual response varies.
    What it is being studied for
    Large randomized trials and product labels support specific uses in type 2 diabetes and chronic weight management; some products also carry additional risk-reduction indications. Check the current label for the exact brand and patient group.
    Potential benefits
    Benefits are established only for particular products, doses and eligible populations. This is not evidence that every compounded or online semaglutide product is equivalent, safe or appropriate.
    Evidence and limitations
    Evidence quality is high for studied, labeled products, including large phase 3 trials. The evidence does not remove the need for diagnosis, contraindication screening and ongoing follow-up.
    Known risks and limitations
    Current product labels describe gastrointestinal effects and important warnings, including gallbladder and pancreatitis concerns and a boxed thyroid C-cell tumor warning for people with relevant personal or family history. Follow the exact label and clinician assessment.
    Regulatory status
    The cited Wegovy label is U.S.-specific and product-specific. It does not establish Colombian registration or availability at YOU Medicine; verify the exact brand and formulation in INVIMA records.

    Selected research references

    Tirzepatide

    Metabolic medicine

    High for labeled products and indications
    What it is
    Tirzepatide is a dual GIP/GLP-1 receptor agonist sold in prescription products with product-specific labels. It is a medicine, not a general-purpose research peptide or supplement.
    How it works
    It activates GIP and GLP-1 receptors involved in glucose control, appetite and gastric emptying. The clinical effect depends on a labeled product and supervised use.
    What it is being studied for
    Randomized trials support specific diabetes and weight-management indications. A head-to-head obesity trial compared tirzepatide with semaglutide; findings apply to the studied regimens and participants.
    Potential benefits
    Clinically meaningful benefits are supported for particular approved products and eligible patients. They do not imply guaranteed individual results or justify using unverified preparations.
    Evidence and limitations
    Evidence is high for the specific labeled indications because it includes phase 3 trials and product labeling. Long-term decisions still require individual risk assessment and monitoring.
    Known risks and limitations
    Labels describe gastrointestinal adverse effects and warnings that can include gallbladder disease, pancreatitis, delayed gastric emptying and a boxed thyroid C-cell tumor warning. Risks and precautions depend on the patient and exact product label.
    Regulatory status
    The cited U.S. Zepbound label is product- and jurisdiction-specific. Colombian/INVIMA registration for the exact product was not verified; U.S. labeling does not establish local availability.

    Selected research references

    Retatrutide

    Investigational metabolic medicine

    Moderate early-stage trial evidence; not established routine care
    What it is
    Retatrutide is an investigational peptide agonist of GIP, GLP-1 and glucagon receptors studied for metabolic conditions. It is not interchangeable with approved GLP-1 medicines.
    How it works
    The multi-receptor design is intended to affect appetite, glucose handling and energy metabolism. Mechanistic rationale and trial results do not establish long-term clinical benefit or safety.
    What it is being studied for
    Published phase 2 trials studied adults with obesity or type 2 diabetes. Later development and trial status must be checked in current registries before making time-sensitive statements.
    Potential benefits
    Early trials reported weight and metabolic changes, which are promising research findings—not a recommendation or a guaranteed result. Replication, longer follow-up and regulatory review remain necessary.
    Evidence and limitations
    Evidence is earlier than the established phase 3 and label evidence for semaglutide or tirzepatide. Phase 2 results cannot establish comparative superiority or long-term safety.
    Known risks and limitations
    Trial safety findings are limited by participant selection and follow-up duration; gastrointestinal effects have been reported in incretin-based studies. The full risk profile is not established for general use.
    Regulatory status
    No approval or Colombian availability is asserted. Verify the current trial registry, FDA status and exact INVIMA record before describing any product as available or authorized.

    Selected research references

    Tesamorelin

    Growth-hormone signaling

    Moderate/high for the specific labeled population
    What it is
    Tesamorelin is a synthetic analog of growth hormone-releasing factor. The U.S. Egrifta SV label covers reduction of excess abdominal fat in adults with HIV-associated lipodystrophy—not general weight loss.
    How it works
    It stimulates pituitary growth-hormone release and raises IGF-1. These hormone effects explain the labeled pharmacology but do not establish anti-aging, bodybuilding or general fat-loss use.
    What it is being studied for
    Clinical trials and the label address visceral abdominal adipose tissue in a specific HIV-related condition. Evidence should not be extrapolated to people without that diagnosis.
    Potential benefits
    A reduction in visceral fat is supported for the labeled group. It is not approved in the cited label as a weight-loss drug and does not guarantee improved health outcomes for other groups.
    Evidence and limitations
    Evidence is condition-specific and includes controlled trials and a U.S. label. This is stronger than experimental peptide evidence but narrow in scope.
    Known risks and limitations
    The label warns about elevated IGF-1, fluid retention, glucose intolerance/diabetes, injection-site reactions and active malignancy. Screening and monitoring are essential under the exact label.
    Regulatory status
    The cited Egrifta SV label is U.S.-specific. Colombian registration for the exact formulation and any local indication was not verified; it must not be described as a general weight-loss approval.

    Selected research references

    AOD-9604

    Metabolic research

    Insufficient for weight-loss claims
    What it is
    AOD-9604 is a modified fragment based on a region of human growth hormone. It is marketed for fat loss, but that marketing should not be confused with evidence that it safely reduces weight in people.
    How it works
    It was developed around a proposed effect on fat metabolism without the full growth-hormone action. The proposed mechanism has not translated into a well-established clinical weight-management medicine.
    What it is being studied for
    Older development reports describe obesity research, but the sources reviewed here do not establish a reproducible, clinically meaningful benefit from high-quality trials.
    Potential benefits
    A possible fat-metabolism effect remains a research proposition. It should not be promoted as a proven fat-loss or body-composition treatment.
    Evidence and limitations
    The available indexed literature is limited and includes development reports rather than a strong evidence base supporting routine use. This is an evidence gap, not proof of benefit.
    Known risks and limitations
    The FDA warns that compounded AOD-9604 may pose immunogenicity and peptide-impurity risks and notes serious adverse events that may be associated with it, though causality is unclear.
    Regulatory status
    No FDA approval for weight loss is identified in the cited sources. Colombian/INVIMA status for a specific product was not verified; do not infer authorization from online sale.

    Selected research references

    MOTS-c

    Mitochondrial and metabolic research

    Preclinical/early; no established therapy
    What it is
    MOTS-c is a short peptide encoded by a small open reading frame in mitochondrial DNA. It is studied as a mitochondrial-derived signaling peptide.
    How it works
    Experimental work links MOTS-c to cellular stress responses and metabolic pathways such as AMPK. Most mechanistic findings come from cells and animals, not therapeutic trials in people.
    What it is being studied for
    Studies explore metabolic homeostasis, exercise adaptation and aging biology. These topics are not evidence that an injected or compounded MOTS-c product treats obesity, diabetes or aging.
    Potential benefits
    Metabolic effects in model systems are scientifically interesting, but there is no established clinical benefit for human weight, energy, longevity or exercise performance.
    Evidence and limitations
    The cited review and foundational studies are predominantly preclinical; human associations are not intervention evidence. Clinical efficacy and long-term safety remain unestablished.
    Known risks and limitations
    Safety data for therapeutic administration are inadequate. Unknown purity, dose, immune response and interactions are concerns for unregulated preparations; do not infer safety from endogenous origin.
    Regulatory status
    No human therapeutic approval is asserted here. Colombian/INVIMA status of any product was not verified, and no clinic availability is claimed.

    Selected research references

    Epitalon

    Aging-biology research

    Very low for longevity claims
    What it is
    Epitalon (also called Epithalon in some publications) is a synthetic tetrapeptide studied in aging biology. Research on a cell line is not evidence that it extends lifespan or prevents disease in people.
    How it works
    Some laboratory papers report telomerase-related or gene-expression findings. These are experimental endpoints; telomere changes in cultured cells are not a validated surrogate for human longevity.
    What it is being studied for
    Published work includes cell and animal experiments and reviews of proposed geroprotective effects. The clinical studies often cited are not sufficient to support routine anti-aging use.
    Potential benefits
    Longevity, sleep or immune benefits are unproven. Do not convert a mechanistic hypothesis or cell-line result into a promise about human health or lifespan.
    Evidence and limitations
    Evidence is very low for clinical outcomes and is dominated by preclinical work and narrative reviews. Independent, well-controlled human trials are needed.
    Known risks and limitations
    Human safety, interactions and long-term consequences are not adequately characterized. Unregulated product identity, purity and sterility add risk.
    Regulatory status
    No approval or Colombian/INVIMA registration for a specific product was verified. A longevity claim or online availability is not evidence of authorization.

    Selected research references

    Thymosin alpha-1

    Immune-related research

    Mixed and indication-specific
    What it is
    Thymosin alpha-1 is a peptide associated with thymic immune signaling. It has been investigated in specific infectious, immune and oncology contexts; it is not a general immune-strengthening supplement.
    How it works
    Research describes effects on T-cell and other immune signaling. Immunomodulation is complex: a proposed immune effect does not mean benefit for every infection, cancer or healthy person.
    What it is being studied for
    Clinical literature includes selected viral infections, sepsis and immune conditions, with results varying by diagnosis, study quality and treatment context. A review is not a universal treatment recommendation.
    Potential benefits
    Any possible benefit must be tied to a specific indication and evidence base. The available literature does not support broad claims of improved immunity, longevity or prevention.
    Evidence and limitations
    Evidence is mixed and condition-specific; the cited review summarizes heterogeneous studies. Clinicians must evaluate current guidelines and local authorization for the exact indication.
    Known risks and limitations
    Potential immune effects and product-specific adverse events require medical oversight. The cited literature does not establish safety for self-directed use or unverified products.
    Regulatory status
    Approvals and availability differ across countries and indications. No current Colombian/INVIMA status was verified for a particular product; do not imply approval from use elsewhere.

    Selected research references

    KPV

    Inflammation research

    Very low for human treatment claims
    What it is
    KPV is a short lysine-proline-valine peptide fragment derived from alpha-melanocyte-stimulating hormone. Research on a fragment does not establish a safe or effective therapeutic product.
    How it works
    Studies propose effects on inflammatory signaling and peptide transport. Most therapeutic findings come from cell and animal models; formulation and route matter.
    What it is being studied for
    Research includes mouse colitis models and experiments on delivery across human skin. A skin-permeation experiment is not a clinical trial proving treatment of a skin or bowel disease.
    Potential benefits
    Anti-inflammatory effects are a research hypothesis. There is no established human benefit for inflammatory bowel disease, skin disease or general inflammation.
    Evidence and limitations
    Evidence is preclinical or focused on delivery methods, with no robust clinical-outcome evidence identified in the reviewed sources.
    Known risks and limitations
    Therapeutic safety, immune reactions, interactions and long-term effects are not established. Compounded or online preparations also raise purity and sterility concerns.
    Regulatory status
    No product-specific approval was verified. Colombian/INVIMA status must be checked against the exact formulation and intended indication.

    Selected research references

    Selank

    Neurobehavioral research

    Low/insufficient for routine anxiety treatment
    What it is
    Selank is a synthetic peptide analog of tuftsin studied mainly in Russian-language and experimental research. Brand, formulation and regulatory status should not be assumed from the name alone.
    How it works
    Proposed neuroimmune and neurotransmitter effects remain investigational. One small acute imaging study compared Selank and Semax with placebo in healthy volunteers; it did not test long-term treatment of anxiety disorders.
    What it is being studied for
    Studies have examined stress-related animal models and short-term brain-connectivity outcomes. These do not establish efficacy for diagnosed anxiety, depression, sleep or cognitive disorders.
    Potential benefits
    An anxiolytic effect is sometimes claimed, but robust independent clinical evidence and product-specific safety data are lacking in the sources reviewed.
    Evidence and limitations
    Evidence is low and geographically limited, with small mechanistic and animal studies. It should not replace evidence-based mental-health assessment or treatment.
    Known risks and limitations
    Reliable long-term safety, interactions and adverse-event rates are not established. Unknown product purity and unsupervised use add risk.
    Regulatory status
    No FDA-approved anxiety indication is identified in the cited sources; current status in other countries and Colombia/INVIMA was not verified.

    Selected research references

    Semax

    Neurological research

    Low/insufficient for general cognitive enhancement
    What it is
    Semax is a synthetic peptide based on an ACTH fragment and studied in selected neurological contexts. Evidence and authorization are jurisdiction-specific and should be checked for the exact product.
    How it works
    Proposed effects on neurotrophic and neurotransmitter systems remain under investigation. A small acute functional-imaging study does not demonstrate improved memory or treatment of a neurological disease.
    What it is being studied for
    Literature includes regional clinical use reports and experimental studies, but the sources reviewed do not establish a high-quality evidence base for general nootropic use.
    Potential benefits
    Cognitive or neuroprotective benefits remain unproven for routine use. Do not infer efficacy from proposed mechanisms or use in another country's practice.
    Evidence and limitations
    Evidence is limited, heterogeneous and not equivalent to large independent trials or internationally accepted guidelines for general cognitive enhancement.
    Known risks and limitations
    Long-term adverse effects, interactions and product quality are insufficiently characterized in the reviewed sources. Neurologic symptoms require appropriate diagnosis, not self-treatment.
    Regulatory status
    No FDA approval for general cognitive enhancement is asserted. Colombian/INVIMA status of a specific product was not verified.

    Selected research references

    DSIP

    Sleep research

    Very low for insomnia treatment
    What it is
    Delta sleep-inducing peptide (DSIP) is a short peptide proposed decades ago as a sleep-related signal. Its natural role, receptor and biological activity remain uncertain.
    How it works
    The hypothesis that DSIP is a central sleep factor has not been clearly established. A later review described the sleep-factor evidence as weak and unresolved.
    What it is being studied for
    A small double-blind study from the early 1990s included 16 chronic-insomnia patients and measured short-term sleep outcomes. It is too small and old to establish modern clinical effectiveness.
    Potential benefits
    The small trial reported some sleep measures, but the overall evidence does not support recommending DSIP for insomnia or sleep improvement.
    Evidence and limitations
    Evidence is very low: one small historical trial and reviews emphasizing unresolved biology. Modern, adequately powered and replicated trials are lacking.
    Known risks and limitations
    Safety, interactions, product quality and long-term effects are not sufficiently characterized. Persistent sleep problems merit assessment for underlying causes and proven care options.
    Regulatory status
    No product-specific FDA or Colombian/INVIMA approval was verified. Do not describe DSIP as an authorized insomnia treatment.

    Selected research references

    Kisspeptin

    Reproductive endocrinology

    Strong for pathway biology; clinical uses remain specific
    What it is
    Kisspeptin is an endogenous peptide that signals through KISS1R and helps regulate gonadotropin-releasing hormone (GnRH) and the reproductive axis.
    How it works
    Human and animal research supports a role in reproductive hormone signaling, puberty and fertility physiology. Altering this pathway is not a general wellness or libido intervention.
    What it is being studied for
    Research explores reproductive endocrinology, including selected fertility and hormone questions. Clinical decisions depend on the diagnosis, sex, reproductive context and specialist assessment.
    Potential benefits
    Potential use is tied to carefully defined reproductive indications under study, not broad anti-aging, weight-loss or sexual-performance claims.
    Evidence and limitations
    The role in reproductive physiology is well described, but that does not make every peptide product or proposed clinical application established. Product-specific therapeutic evidence remains indication-dependent.
    Known risks and limitations
    Interfering with reproductive hormone signaling can have diagnosis-dependent effects. Safety and monitoring must be evaluated by a clinician; no self-directed use is appropriate.
    Regulatory status
    Authorization is product- and indication-specific. No current Colombian/INVIMA registration for a specific kisspeptin product was verified.

    Selected research references

    Bremelanotide (PT-141)

    Sexual-health medicine

    Moderate/high for the labeled population and outcomes
    What it is
    Bremelanotide is a melanocortin-receptor agonist marketed in the U.S. as Vyleesi. Its label is limited to premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD) causing distress.
    How it works
    It acts on melanocortin pathways in the central nervous system and is not a blood-flow drug like sildenafil. The mechanism does not mean it treats every cause of low desire.
    What it is being studied for
    Phase 3 RECONNECT studies evaluated desire and distress in the specific labeled population. Other uses, including in men or postmenopausal women, are not established by that approval.
    Potential benefits
    The trials found benefit on selected desire and distress measures, but response varies and the label does not promise an increase in satisfying sexual events. It is not a general performance enhancer.
    Evidence and limitations
    Evidence is moderate to high for the defined HSDD population and studied outcomes, based on controlled phase 3 trials and a U.S. label. Evidence for off-label populations is more limited.
    Known risks and limitations
    The label includes nausea, flushing, headache, injection-site reactions, temporary blood-pressure rise, and focal hyperpigmentation. It is not appropriate with uncontrolled hypertension or known cardiovascular disease.
    Regulatory status
    The cited Vyleesi label is U.S.-specific and narrow. Colombian/INVIMA status for a specific product was not verified; this does not establish local availability or a broader indication.

    Selected research references

    Cagrilintide

    Investigational metabolic medicine

    Moderate early-stage evidence; approval status must be checked
    What it is
    Cagrilintide is a long-acting amylin analog studied for weight management. Cagrilintide alone and CagriSema (cagrilintide plus semaglutide) are distinct interventions with different evidence.
    How it works
    Amylin-pathway activity may affect satiation and appetite. Mechanistic rationale does not establish a long-term benefit or make combination-trial results attributable to cagrilintide alone.
    What it is being studied for
    A phase 2 trial studied cagrilintide alone in adults with overweight or obesity; separate trials studied combinations with semaglutide. The populations and treatment arms must be distinguished when interpreting results.
    Potential benefits
    Early weight-management findings are research results, not a personal recommendation or guarantee. Combination data cannot be presented as proof of the same result from cagrilintide alone.
    Evidence and limitations
    There is phase 2 evidence for monotherapy and later-stage evidence for a combination. Long-term safety, independent replication and current regulatory status require review.
    Known risks and limitations
    Trial reports include gastrointestinal tolerability considerations; the full long-term profile and risks for different patients remain under study. Do not use an unapproved or unverified preparation.
    Regulatory status
    No product-specific approval or Colombian/INVIMA registration was verified. Check the current registry and exact formulation; trial participation is not product approval.

    Selected research references

    Safety: product quality is part of the evidence

    An ingredient name on a label does not confirm identity, purity, concentration, sterility or cold-chain handling. FDA safety notices identify specific compounding concerns for several peptides in this guide. Online products marked “research use only” are not evidence of human-grade quality or lawful medical use.

    Risks may include contamination, immune reactions, peptide impurities, dose variability, interactions and unknown long-term effects. For approved medicines, use the current product label and a clinician’s assessment rather than extrapolating from another brand or route.

    Colombia and INVIMA: verify the exact product

    U.S. FDA authorization does not establish registration or availability in Colombia. Product registrations can differ by brand, formulation, route, indication and importer. This draft has not verified an INVIMA record for each compound and does not claim any investigational peptide is approved or offered by YOU Medicine.

    Before a clinician or patient relies on a product’s legal status, verify the exact product and indication in the current INVIMA record and obtain appropriate regulatory advice. A clinic should be able to explain sourcing, documentation, risks, alternatives and follow-up in writing.

    How to choose a peptide clinic in Medellín: questions to ask

    • What diagnosis is being addressed, and what evidence supports this exact product for that diagnosis?
    • Is this the same formulation and route studied in the cited trials or product label?
    • What are the known risks, unknowns, contraindications and alternatives?
    • What product-specific INVIMA documentation and sourcing information can be provided?
    • Who is responsible for prescribing, monitoring side effects and follow-up?
    • What would make the clinician recommend against treatment?

    Medically supervised peptide information at YOU Medicine

    YOU Medicine is in El Poblado, Medellín, at Cl. 10B #35-08, Edificio Santacoloma, Local 2. The existing peptide therapy and peptide library pages explain the clinic’s consultation pathway and selected educational profiles. The location does not mean every compound in this comparison is prescribed, stocked or appropriate for a patient. Ask the medical team about your diagnosis and options; the clinician may recommend a different approach or no peptide treatment.

    Request a peptide consultation in Medellín

    If you want to discuss a diagnosis or treatment question, use the existing consultation pathway or WhatsApp contact. A clinician can review your situation and explain options; this guide is not an offer or recommendation for a particular peptide.

    Book a medical consultationAsk a question on WhatsApp

    Frequently asked questions

    Which peptide is best for weight loss in Medellín?

    There is no best peptide for everyone. Prescription medicines such as semaglutide or tirzepatide have product-specific evidence and indications, but a clinician must assess eligibility, risks and local product status. Investigational compounds are not interchangeable with approved medicines.

    Are research peptides approved in Colombia?

    Approval is product-, formulation- and indication-specific. This guide has not verified individual INVIMA registrations. Check the current INVIMA record; online sale or a U.S. label does not prove Colombian authorization.

    Does a peptide that raises growth hormone build muscle or slow aging?

    A hormone-marker change is not proof of muscle gain, slower aging or better health. Clinical outcomes and risks must be studied for each compound and use.

    Are BPC-157 and TB-500 proven for injury recovery?

    No robust clinical evidence establishes them as effective injury treatments. Most research is preclinical, and the FDA has raised safety concerns about compounded forms of these substances.

    Is retatrutide available as a routine treatment?

    The cited evidence includes phase 2 research. Current trial and regulatory status must be checked in official registries; this article does not claim approval or availability.

    Does YOU Medicine offer all 20 peptides?

    No such claim is made. The list is an educational comparison of research topics and selected prescription medicines. Ask the clinic whether a specific, medically appropriate option is available and locally authorized.

    Can I order peptide vials online and use them myself?

    Self-use of unverified products can expose you to mislabeling, contamination, dosing and medical risks. Discuss any treatment with a licensed clinician and verify the exact product and regulatory documentation.

    Does U.S. FDA approval apply in Colombia?

    No. U.S. FDA authorization is specific to U.S. products and indications; it does not establish Colombian registration. Verify the exact product with INVIMA.

    References and evidence notes

    1. Panda et al. Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review. HSS Journal. 2025. PMID 40756949. — Review found the literature is mainly preclinical with sparse clinical evidence.
    2. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021. PMID 34324435. — Observational report; cannot establish efficacy or causality.
    3. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Accessed 2026-11-04. — FDA safety concerns are not an approval or an efficacy study.
    4. Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. JAAOS Global Research & Reviews. 2026. PMID 41490200. — Broad review; does not establish a TB-500 treatment indication.
    5. Schänzer et al. Detection of peptidic drugs, drug candidates and analogs in sports doping. Expert Review of Proteomics. 2015. PMID 25382550. — Anti-doping analytical literature, not evidence of clinical benefit.
    6. Topically applied GHK as an anti-wrinkle peptide: Advantages, problems and prospective. BioImpacts. 2025. PMID 39963574. — Discusses topical skin delivery and the limits of the evidence.
    7. Pickart et al. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. International Journal of Molecular Sciences. 2018. PMID 29986520. — Mechanistic review; not proof of clinical effectiveness.
    8. Are We Ready to Measure Skin Permeation of Modern Antiaging GHK-Cu Tripeptide Encapsulated in Liposomes? Molecules. 2025. PMID 39795193. — Highlights delivery/formulation challenges for topical use.
    9. Teichman et al. Prolonged stimulation of growth hormone and IGF-I secretion by CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006. PMID 16352683. — Hormone markers, not proof of anti-aging or performance outcomes.
    10. Raun et al. Ipamorelin, the first selective growth hormone secretagogue. European Journal of Endocrinology. 1998. PMID 9849822. — Early pharmacology work; read with FDA safety notice.
    11. Wilding et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021. PMID 33567185. — Evidence for the studied product, regimen and eligible population.
    12. Safety of Semaglutide. Frontiers in Endocrinology. 2021. PMID 34305810. — Review of product-specific safety evidence.
    13. U.S. FDA prescribing information: Wegovy (semaglutide), label cited in the existing clinic education source; verify current revision before publication. — U.S. product label; not a Colombian registration record.
    14. Aronne et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. New England Journal of Medicine. 2025. PMID 40353578. — Head-to-head results apply to the trial's participants and regimens.
    15. Frías et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine. 2021. PMID 34170647. — Diabetes trial; not interchangeable with every weight-management indication.
    16. U.S. FDA prescribing information: Zepbound (tirzepatide), label cited in the existing clinic education source; verify current revision before publication. — U.S. product label; not a Colombian registration record.
    17. Jastreboff et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. New England Journal of Medicine. 2023. PMID 37366315. — Early trial evidence; not an approval or long-term outcome study.
    18. Rosenstock et al. Retatrutide for people with type 2 diabetes: a randomized phase 2 trial. Lancet. 2023. PMID 37385280. — Evidence for the studied diabetes population only.
    19. ClinicalTrials.gov public registry search for retatrutide studies; status is time-sensitive and must be checked again before publication. — Registry entries do not mean a medicine is approved or commercially available.
    20. U.S. FDA prescribing information: Egrifta SV (tesamorelin), label cited in the existing clinic education source; verify current revision before publication. — Narrow HIV-lipodystrophy indication; not general weight loss.
    21. Clinical Predictors of Liver Fibrosis Presence and Progression in HIV-Associated NAFLD, leveraging a randomized tesamorelin trial. Clinical Infectious Diseases. 2021. PMID 32270862. — HIV-associated condition; not evidence for general fat loss.
    22. AOD-9604 Metabolic. Current Opinion in Investigational Drugs. 2004. PMID 15134286. — Development context, not proof of efficacy; FDA safety notice also applies.
    23. MOTS-c: A promising mitochondrial-derived peptide for therapeutic exploitation. Frontiers in Endocrinology. 2023. PMID 36761202. — Review describes research potential, not an established human therapy.
    24. Lee et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015. PMID 25738459. — Key findings are preclinical; not a human-treatment trial.
    25. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021. PMID 33473109. — Model-system findings do not establish human performance benefits.
    26. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025. PMID 40908429. — Cell-line outcomes are not evidence of longer human life.
    27. Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties. International Journal of Molecular Sciences. 2025. PMID 40141333. — Narrative review; claims need independent clinical verification.
    28. Thymosin alpha 1: A comprehensive review of the literature. World Journal of Virology. 2020. PMID 33362999. — Summarizes heterogeneous condition-specific research.
    29. Thymosin alpha-1 treatment in chronic hepatitis B. Expert Opinion on Biological Therapy. 2015. PMID 25640173. — Does not establish broad immune enhancement.
    30. Critical role of PepT1 and therapeutic benefits of KPV in a murine colitis-associated cancer model. Cellular and Molecular Gastroenterology and Hepatology. 2016. PMID 27458604. — Animal model, not a human treatment trial.
    31. Transdermal Iontophoretic Delivery of Lysine-Proline-Valine (KPV) Peptide Across Microporated Human Skin. Journal of Pharmaceutical Sciences. 2018. PMID 28343991. — Skin-delivery experiment, not evidence of clinical benefit.
    32. Functional Connectomic Approach to Studying Selank and Semax Effects. Doklady Biological Sciences. 2020. PMID 32342318. — Healthy-volunteer imaging outcomes, not a disorder-treatment trial.
    33. Selank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats. Bulletin of Experimental Biology and Medicine. 2022. PMID 36322304. — Rat model; does not establish human anxiety treatment.
    34. PubMed-indexed literature on Semax remains heterogeneous; the cited human study is acute and mechanistic, not a general cognition treatment trial. — No high-quality evidence for general cognitive enhancement was established in this review.
    35. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients: a double-blind study. Neuropsychobiology. 1992. PMID 1299794. — Sixteen participants; far too small to establish routine treatment.
    36. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006. PMID 16539679. — Review describes the sleep-factor hypothesis as weak and unresolved.
    37. The Role of Kisspeptin in the Control of the Hypothalamic-Pituitary-Gonadal Axis and Reproduction. Frontiers in Endocrinology. 2022. PMID 35837314. — Supports reproductive pathway biology, not a general wellness indication.
    38. Metabolic regulation of kisspeptin—the link between energy balance and reproduction. Nature Reviews Endocrinology. 2020. PMID 32427949. — Review of physiology and metabolic regulation.
    39. Prespecified and Integrated Subgroup Analyses from the RECONNECT Phase 3 Studies of Bremelanotide. Journal of Women's Health. 2022. PMID 35230162. — Applies to the narrow studied HSDD population.
    40. U.S. FDA prescribing information: Vyleesi (bremelanotide), label cited in the existing clinic education source; verify current revision before publication. — Narrow U.S. indication; not a general libido treatment.
    41. Lau et al. Once-weekly cagrilintide for weight management in people with overweight and obesity: phase 2 trial. Lancet. 2022. PMID 34798060. — Early-stage monotherapy trial; not proof of approval or long-term outcomes.
    42. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2025. PMID 40544433. — CagriSema combination findings must not be attributed to cagrilintide alone.

    Related information

    This guide is general education, not medical advice. It does not rank or recommend products or imply that they are available at YOU Medicine. Discuss evidence, risks and regulation for your situation with a qualified clinician.